Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017136342) FULVESTRANT FOR INDUCING IMMUNE-MEDIATED CYTOTOXIC LYSIS OF CANCER CELLS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/136342 International Application No.: PCT/US2017/015829
Publication Date: 10.08.2017 International Filing Date: 31.01.2017
IPC:
A61K 31/565 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
56
Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
565
not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
Applicants:
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; Office of Technology Transfer National Institutes of Health 6011 Executive Boulevard, Suite 325 MSC 7660 Bethesda, Maryland 20892-7660, US
Inventors:
PALENA, Claudia M.; US
SCHLOM, Jeffrey; US
FERRER, Marc; US
Agent:
MEJDRICH, Rachel J.; US
LEYDIG, VOIT & MAYER, LTD.; LEYDIG, VOIT & MAYER, LTD. Two Prudential Plaza, Suite 4900 180 North Stetson Avenue Chicago, Illinois 60601, US
Priority Data:
62/290,11702.02.2016US
Title (EN) FULVESTRANT FOR INDUCING IMMUNE-MEDIATED CYTOTOXIC LYSIS OF CANCER CELLS
(FR) FULVESTRANT INDUISANT LA LYSE CYTOTOXIQUE À MÉDIATION IMMUNITAIRE DES CELLULES CANCÉREUSES
Abstract:
(EN) A method of enhancing immune-mediated lysis of mesenchymal cancer cells and a method of sensitizing mesenchymal cancer cells to chemotherapy or immune-mediated lysis are provided. The methods comprise comprising administering fulvestrant to the cancer cells. A method of treating lung cancer comprising administering a combination of fulvestrant and an immune-mediated therapy to a patient also is provided.
(FR) L'invention concerne un procédé d'amélioration de la lyse à médiation immunitaire de cellules cancéreuses mésenchymateuses et un procédé de sensibilisation des cellules cancéreuses à une chimiothérapie ou une lyse à médiation immunitaire. Les procédés comprennent l'administration de fulvestrant aux cellules cancéreuses. L'invention concerne également un procédé de traitement d'un cancer pulmonaire comprenant l'administration d'une combinaison de fulvestrant et d'un traitement à médiation immunitaire à un patient.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)